Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors - Trial NCT06248697
Access comprehensive clinical trial information for NCT06248697 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Cell Therapy Group Co.,Ltd and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Cell Therapy Group Co.,Ltd
Timeline & Enrollment
Phase 1
Jan 01, 2023
Dec 31, 2026
Primary Outcome
Dose-limiting toxicity๏ผDLT๏ผ
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and
 tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T
 cells secreting PD-1 and CTLA-4 nanobodies (ฮฑPD1/CTLA-4-MSLN-CAR T cells) in patients with
 solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06248697
Non-Device Trial